Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Receivables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Receivables for 3 consecutive years, with $114609.0 as the latest value for Q4 2025.

  • On a quarterly basis, Receivables changed N/A to $114609.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $114609.0, a N/A change, with the full-year FY2025 number at $1.5 million, changed N/A from a year prior.
  • Receivables was $114609.0 for Q4 2025 at Outlook Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.8 million in Q2 2025 to a low of $114609.0 in Q4 2025.